BMI View: We expect a moderate increase in Bahraini medicine sales in 2017, which will gradually gainmomentum over the long term. The demand for prescription drugs will be boosted by the eventualimplementation of the national health insurance scheme in the coming years, coupled with a rising chronicdisease burden. However, Bahrain's small population and unfavourable risk profile will continue to limitmultinational drugmakers' interest in the market.
Headline Expenditure Projections
Pharmaceuticals: BHD148mn (USD393mn) in 2016 to BHD154mn (USD409mn) in 2017; +4.2% inboth local currency and US dollar terms. Forecast revised upwards slightly from last quarter.
Healthcare: BHD740mn (USD1.96bn) in 2016 to BHD796mn (USD2.11bn) in 2017; +7.6% in localcurrency terms and US dollar terms. Forecast revised upwards from last quarter.